Skip to main content

Table 1 Patient characteristics and baseline sHER2 levels

From: Monitoring serum HER2 levels in breast cancer patients

  

N

sHer2 values

p values a

 

Patients (N)

118

5.750 +/− 3.495

 

Race

Asian

7

9.11

0.041

Caucasian

81

5.23

African American

30

6.36

Age at diagnosis(years)

mean ± sd

 

54.10 +/−13.81

0.813

≤45

32

5.38

>45

86

5.89

Tumor size (cm)

mean ± sd

 

2.8- +/− 2.33

.852

T1

<2

53

5.49

T2

2-5

53

5.81

T3

>5

11

6.27

 

N/A

1

  

(+) axilla lymph node(s)

0

63

5.47

1.000

≥1

55

6.07

Receptor subtype

tHer2+

23

8.18

.032

tHer2-, ER/PR+

77

5.02

TNBC

18

5.79

Clinical Outcome

Disease Present

12

8.50

0.007

Disease Absent

106

5.44

Length of Follow Up (Months)

Mean ± sd

23.51 +/− 11.38

  

Median

21.32

  
  1. Abbreviations: ER estrogen receptor, PR progesterone receptor, sHER2, soluble human epidermal growth factor receptor 2. aThis P value was determined using the Fisher’s test. N/A: in 1 patient, relevant information (e.g., tumor size) was missing